06 May 2021>: Clinical Research
Establishment and Verification of a Prediction Model for Symptomatic Radiation Pneumonitis in Patients with Esophageal Cancer Receiving Radiotherapy
Liu-Ting Yang 1ABCDEFG , Lei Zhou 1BC , Long Chen 1ACDE , Shi-Xiong Liang 1ADE , Jiang-Qiong Huang 1DEF , Xiao-Dong Zhu 12ACDEF*DOI: 10.12659/MSM.930515
Med Sci Monit 2021; 27:e930515
Table 3 Univariate analysis of clinicopathologic, dosimetric, and inflammatory parameters in predicting symptomatic radiation pneumonitis.
Parameters | χ2 | P |
---|---|---|
Sex (Male vs Female) | 0.087 | 1.000 |
Age (≤60 vs >60; years) | 0.065 | 0.799 |
Smoking (yes vs no) | 0.120 | 0.729 |
Smoking index ( | 0.009 | 0.926 |
Drinking (yes vs no) | 0.042 | 0.838 |
Location (Cervical/upper/middle/lower/multifocal) | 3.843 | 0.428 |
T stage (T1–T2 vs T3–T4) | 2.369 | 0.228 |
N stage (N0–N1 vs N2–N3) | 0.244 | 0.621 |
M stage (M0 vs M1) | 1.719 | 0.340 |
Clinical stages (I–II vs III–IV) | 0.358 | 0.809 |
Chemotherapy (PF regimen vs TP regimen) | 2.797 | 0.094 |
Chemotherapy cycle ( | 1.515 | 0.218 |
Pulmonary bulla (0/1/2/3) | 2.281 | 0.516 |
Fractional dose ( | 0.357 | 0.770 |
MLD ( | 5.336 | 0.021 |
V5 ( | 6.471 | 0.011 |
V10 ( | 7.262 | 0.007 |
V15 ( | 4.811 | 0.028 |
V20 ( | 4.813 | 0.028 |
V25 ( | 1.66 | 0.198 |
V30 ( | 1.594 | 0.207 |
V35 ( | 1.432 | 0.231 |
V40 ( | 1.378 | 0.240 |
NLR during RT ( | 3.824 | 0.051 |
PLR during RT ( | 6.504 | 0.004 |
LMR during RT ( | 5.017 | 0.025 |
SII during RT ( | 4.477 | 0.034 |
NLR at the end of RT ( | 11.728 | 0.001 |
PLR at the end of RT ( | 6.370 | 0.012 |
LMR at the end of RT ( | 9.266 | 0.002 |
SII at the end of RT ( | 6.346 | 0.012 |
PF – platinum-fluorouracil; TP – taxus-platinum; MLD – mean lung dose; NLR – neutrophil-to-lymphocyte ratio; RT – radiation therapy; PLR – platelet-to-lymphocyte ratio; LMR – lymphocyte-to-monocyte ratio; SII – systemic immune inflammation index. |